Bio

Joyce is a board certified internist and endocrinologist with added qualifications in geriatrics. She has been in industry for 13 years at Merck and Regeneron in all stages of clinical development and in strategic program leadership. She has extensive experience in both common and rare disease clinical development and strategy across a spectrum of therapeutic areas. She has developed small molecules, insulins and monoclonal antibodies for diabetes, lipids and obesity, including Januvia, taranabant, insulin glargine biosimilar and Praluent. Ferox is her second start-up venture in the biopharmaceutical space. Prior to industry she spent 15 years as an NIH-funded academic physician and has published over 40 manuscripts in the field of metabolic disorders.